<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: (1) To classify an intermediate group of patients (IntAPS) with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e>-like disease either as primary (PAPS) or secondary APS (SAPS) and to discuss 2 different classifications </plain></SENT>
<SENT sid="1" pm="."><plain>(2) To compare patients of a division of rheumatology with either PAPS or SAPS </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients with APS and patients with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) followed at the Department of Rheumatology, University Hospital Bichat, Paris, from 1987 to 1996 were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>A chart review and a standardized telephone interview in 1997 completed the data of this study </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: (1) We found a total of 108 patients with APS: 22 with PAPS, 69 with SAPS, and 17 with IntAPS </plain></SENT>
<SENT sid="5" pm="."><plain>The group of IntAPS did not differ from PAPS in any clinical or laboratory signs with the exception of antibodies to dsDNA and to extractable nuclear antigen (ENA) </plain></SENT>
<SENT sid="6" pm="."><plain>Between IntAPS and SAPS, there were several significant differences in clinical signs of SLE (malar <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, discoid <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, <z:hpo ids='HP_0002829'>arthralgia</z:hpo>) and in laboratory values (<z:mp ids='MP_0000221'>leukocytopenia</z:mp>) </plain></SENT>
<SENT sid="7" pm="."><plain>(2) Comparison of PAPS and SAPS showed statistically significant differences for positive Coombs' test, <z:mp ids='MP_0000221'>leukocytopenia</z:mp>, <z:hpo ids='HP_0001888'>lymphocytopenia</z:hpo>, <z:hpo ids='HP_0003493'>antinuclear antibodies</z:hpo>, antibodies to dsDNA and to ENA, and hypocomplementemia </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The mainstay of the diagnosis of APS is the clinical event of <z:mp ids='MP_0005048'>thrombosis</z:mp> or <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriage</z:e> in the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Less important are laboratory values, which may help to differentiate PAPS from SAPS in order to initiate adequate therapy (e.g., anticoagulation in the first and additional <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> in the second) </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with IntAPS are more likely to be integrated into the group of PAPS than in the group of SAPS; therefore, special exclusion criteria for PAPS are not appropriate </plain></SENT>
</text></document>